BACKGROUND: Exposure to indoor allergens contributes to increased asthma morbidity. The Inner-City Asthma Study, a randomized trial involving home environmental allergen and irritant remediation among children aged 6 through 11 years with moderate-to-severe asthma, successfully reduced asthma symptoms. A cost-effectiveness analysis can help stakeholders to evaluate the potential costs and benefits of adopting such a program. OBJECTIVE: We sought to assess the cost-effectiveness of the environmental intervention of the Inner-City Asthma Study. METHODS:Incremental cost-effectiveness ratios for a 2-year study period were calculated. Health outcome was measured as symptom-free days. Resource use measures included ambulatory visits, hospitalizations, and pharmaceutical use. CIs were obtained by using bootstrapping. RESULTS: The intervention, which cost $1469 per family, led to statistically significant reductions in symptom days, unscheduled clinic visits, and use of beta-agonist inhalers. Over the year of the intervention and a year of follow-up, the intervention cost was $27.57 per additional symptom-free day (95% CI, $7.46-$67.42). Subgroup analysis showed that targeting the intervention to selected high-risk subgroups did not reduce the incremental cost-effectiveness ratio. CONCLUSIONS: A targeted home-based environmental intervention improved health and reduced service use in inner-city children with moderate-to-severe asthma. The intervention is cost-effective when the aim is to reduce asthma symptom days and the associated costs.
RCT Entities:
BACKGROUND: Exposure to indoor allergens contributes to increased asthma morbidity. The Inner-City Asthma Study, a randomized trial involving home environmental allergen and irritant remediation among children aged 6 through 11 years with moderate-to-severe asthma, successfully reduced asthma symptoms. A cost-effectiveness analysis can help stakeholders to evaluate the potential costs and benefits of adopting such a program. OBJECTIVE: We sought to assess the cost-effectiveness of the environmental intervention of the Inner-City Asthma Study. METHODS: Incremental cost-effectiveness ratios for a 2-year study period were calculated. Health outcome was measured as symptom-free days. Resource use measures included ambulatory visits, hospitalizations, and pharmaceutical use. CIs were obtained by using bootstrapping. RESULTS: The intervention, which cost $1469 per family, led to statistically significant reductions in symptom days, unscheduled clinic visits, and use of beta-agonist inhalers. Over the year of the intervention and a year of follow-up, the intervention cost was $27.57 per additional symptom-free day (95% CI, $7.46-$67.42). Subgroup analysis showed that targeting the intervention to selected high-risk subgroups did not reduce the incremental cost-effectiveness ratio. CONCLUSIONS: A targeted home-based environmental intervention improved health and reduced service use in inner-city children with moderate-to-severe asthma. The intervention is cost-effective when the aim is to reduce asthma symptom days and the associated costs.
Authors: Daphne Koinis-Mitchell; Elizabeth L McQuaid; Ronald Seifer; Sheryl J Kopel; Cynthia Esteban; Glorisa Canino; Cynthia Garcia-Coll; Robert Klein; Gregory K Fritz Journal: J Pediatr Psychol Date: 2007-01-11
Authors: Amanda Savage Brown; Sheri Disler; Laura Burns; Angie Carlson; Adam Davis; Cizely Kurian; Dolores Weems; Kristen Wilson Journal: J Urban Health Date: 2011-02 Impact factor: 3.671
Authors: Daphne Koinis-Mitchell; Amy F Sato; Sheryl J Kopel; Elizabeth L McQuaid; Ronald Seifer; Robert Klein; Cynthia Esteban; Debra Lobato; Alexander N Ortega; Glorisa Canino; Gregory K Fritz Journal: J Pediatr Psychol Date: 2011-07-10
Authors: Helen E Jack; Sophia D Arabadjis; Lucy Sun; Erin E Sullivan; Russell S Phillips Journal: J Gen Intern Med Date: 2016-12-05 Impact factor: 5.128
Authors: Lara J Akinbami; Sean D Sullivan; Jonathan D Campbell; Robert W Grundmeier; Tina V Hartert; Todd A Lee; Robert A Smith Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Cynthia A Esteban; Robert B Klein; Sheryl J Kopel; Elizabeth L McQuaid; Gregory K Fritz; Ronald Seifer; Daniel York; Natalie Golova; Barbara Jandasek; Daphne Koinis-Mitchell Journal: Pediatr Allergy Immunol Pulmonol Date: 2014-06-01 Impact factor: 1.349